Abiopharma

🔍 Tan Kwang Hooi (Executive)

Company: FLEX LTD. (FLEX)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 48,582 shares of Ordinary Shares (Direct)
  Date: 2026-05-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 282,218.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,932 shares of Ordinary Shares at $138.5755 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 280,286.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 2,398 shares of Ordinary Shares at $139.66 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 277,888.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 2,830 shares of Ordinary Shares at $140.6323 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 275,058.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 1,731 shares of Ordinary Shares at $141.526 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 273,327.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 4,487 shares of Ordinary Shares at $142.7523 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 268,840.00 | transaction_form_type: 4 | Footnotes: F2, F7
• Sold 8,081 shares of Ordinary Shares at $143.5145 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 260,759.00 | transaction_form_type: 4 | Footnotes: F2, F8
• Sold 4,716 shares of Ordinary Shares at $144.3206 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 256,043.00 | transaction_form_type: 4 | Footnotes: F2, F9, F10

Footnotes:

• F1: On June 14, 2023, the Reporting Person was awarded performance-based restricted share units ("PSUs") within a preset range, with the actual number contingent upon the achievement of a certain performance criterion with respect to the three-year performance period ending on March 31, 2026. The Issuer certified the achievement of the performance criterion, and the PSUs fully vested, on May 8, 2026, and were subject to applicable taxes upon delivery.
• F2: The sales reported in this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs.
• F3: Price reflects weighted average sales price; actual sales prices ranged from $138.11 to $139.108. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F4: Price reflects weighted average sales price; actual sales prices ranged from $139.11 to $140.095. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F5: Price reflects weighted average sales price; actual sales prices ranged from $140.12 to $141.07. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F6: Price reflects weighted average sales price; actual sales prices ranged from $141.12 to $142.01. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F7: Price reflects weighted average sales price; actual sales prices ranged from $142.125 to $143.12. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F8: Price reflects weighted average sales price; actual sales prices ranged from $143.13 to $144.12. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F9: Price reflects weighted average sales price; actual sales prices ranged from $144.13 to $144.765. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F10: Includes the following: (1) 23,981 unvested restricted share units ("RSUs"), which will vest in two equal annual installments beginning on June 12, 2026; (2) 21,964 unvested RSUs, which will vest in three equal annual installments beginning on June 12, 2026; (3) 16,195 unvested RSUs, which will vest on June 14, 2026; and (4) 72,578 unvested RSUs, which will vest on September 25, 2027.
• F11: Each unvested RSU represents a contingent right to receive one unrestricted, fully transferable share for each vested RSU which has not been previously forfeited.